Cargando…

SARS-CoV-2 Spike Antibody Levels Trend among Sinopharm Vaccinated People

Detalles Bibliográficos
Autores principales:	Saeed, Umar, Uppal, Sara Rizwan, Piracha, Zahra Zahid, Uppal, Rizwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426791/ https://www.ncbi.nlm.nih.gov/pubmed/34568189 http://dx.doi.org/10.18502/ijph.v50i7.6640

Ejemplares similares

SARS-CoV-2 induced hepatic injuries and liver complications
por: Saeed, Umar, et al.
Publicado: (2022)

Evaluation of SARS-CoV-2 antigen-based rapid diagnostic kits in Pakistan: formulation of COVID-19 national testing strategy
por: Saeed, Umar, et al.
Publicado: (2021)

Sinopharm Vaccine, SARS-CoV-2 Breakthrough Infections and Hemoglobinopathies
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

583. SARS-CoV-2 Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians
por: Lopera, Maria, et al.
Publicado: (2021)

Anti-Spike and Neutralizing Antibodies after Two Doses of COVID-19 Sinopharm/BIBP Vaccine
por: Omran, Eman A., et al.
Publicado: (2022)

PIN1 and PIN4 inhibition via parvulin impeders Juglone, PiB, ATRA, 6,7,4′-THIF, KPT6566, and EGCG thwarted hepatitis B virus replication
por: Saeed, Umar, et al.
Publicado: (2023)

Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome
por: Boualila, L., et al.
Publicado: (2022)

The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine
por: Farid, Eman, et al.
Publicado: (2022)

Lethal Toxic Epidermal Necrolysis probably induced by Sinopharm COVID-19 vaccine
por: Seck, B., et al.
Publicado: (2022)

Partial protection of Sinopharm vaccine against SARS COV2 during recent outbreak in Bahrain
por: Jahromi, Mohamed, et al.
Publicado: (2021)

Abducense nerve palsy following BBIBP-CorV (Sinopharm) COVID-19 vaccine
por: Khalili, M.R., et al.
Publicado: (2022)

Contemplating the Importance of Toll-like Receptors I and II Regarding Human Viral Pathogenesis
por: Saeed, Umar, et al.
Publicado: (2014)

Side effects and perceptions following Sinopharm COVID-19 vaccination
por: Saeed, Balsam Qubais, et al.
Publicado: (2021)

Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation
por: Ma, Jing, et al.
Publicado: (2022)

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study
por: Safarnezhad Tameshkel, Fahimeh, et al.
Publicado: (2023)

Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report
por: Karimi, Mehran, et al.
Publicado: (2022)

Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
por: Alqassieh, Rami, et al.
Publicado: (2021)

Cord blood antibodies following BBIBP‐CorV (Sinopharm) vaccination during pregnancy
por: Hantoushzadeh, Sedigheh, et al.
Publicado: (2023)

Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
por: Wang, Chao, et al.
Publicado: (2022)

Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm)
por: Cvetkovic-Vega, Aleksandar, et al.
Publicado: (2023)

Evaluation of SARS-CoV-2 Serum Level in Patients Vaccinated With Sinopharm/BBIBP-CorV With Kidney Transplantation
por: Rahbar, Maryam, et al.
Publicado: (2022)

Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Longer Intervals before Vaccination Increase Spike Antibody Titers in Individuals Previously Infected with SARS-CoV-2
por: Bi, Xiuqiong, et al.
Publicado: (2022)

The Prevalence of Side Effects of Sinopharm COVID-19 Vaccine: An Experience From Pakistan
por: Haider, Taimur, et al.
Publicado: (2023)

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Fixed drug eruption after the Sinopharm COVID‐19 vaccine
por: Rekabi, Mahsa, et al.
Publicado: (2022)

Positive Predictive Value of SARS-CoV-2 Spike Protein Antibody Test after COVID-19 Vaccination Policies
por: Sookaromdee, Pathum, et al.
Publicado: (2023)

The Functional Consequences of the Novel Ribosomal Pausing Site in SARS-CoV-2 Spike Glycoprotein RNA
por: Postnikova, Olga A., et al.
Publicado: (2021)

SARS-CoV-2 related liver impairment – perception may not be the reality
por: Philips, Cyriac Abby, et al.
Publicado: (2020)

PB2230: EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT
por: Karimi, M., et al.
Publicado: (2022)

Understanding perception and acceptance of Sinopharm vaccine and vaccination against COVID–19 in the UAE
por: Ahamed, Faheem, et al.
Publicado: (2021)

SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Recombinant subunits of SARS‐CoV‐2 spike protein as vaccine candidates to elicit neutralizing antibodies
por: Noorabad Ghahroodi, Faezeh, et al.
Publicado: (2022)

Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
por: Jeewandara, Chandima, et al.
Publicado: (2022)

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine
por: Ferenci, Tamás, et al.
Publicado: (2022)

Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results
por: Perkmann, Thomas, et al.
Publicado: (2021)

Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals
por: Faustini, Sian, et al.
Publicado: (2022)

Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
por: Hosseinzadeh, Rezvan, et al.
Publicado: (2022)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_emv6mub543jj5ppsj0ke6jvg86